Louise Chen
Stock Analyst at Cantor Fitzgerald
(2.99)
# 1,235
Out of 4,667 analysts
284
Total ratings
38.83%
Success rate
0.69%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRO Spero Therapeutics | Reiterates: Overweight | n/a | $1.20 | - | 5 | Nov 15, 2024 | |
| NVO Novo Nordisk | Reiterates: Overweight | $160 | $103.15 | +55.11% | 20 | Nov 6, 2024 | |
| PCVX Vaxcyte | Reiterates: Overweight | n/a | $85.96 | - | 6 | Nov 6, 2024 | |
| PFE Pfizer | Reiterates: Overweight | $45 | $24.80 | +81.43% | 30 | Oct 25, 2024 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $26.23 | - | 7 | Oct 25, 2024 | |
| JNJ Johnson & Johnson | Reiterates: Overweight | $215 | $153.87 | +39.73% | 40 | Oct 16, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | n/a | $8.97 | - | 5 | Oct 11, 2024 | |
| MRK Merck & Co. | Reiterates: Overweight | $155 | $97.44 | +59.07% | 25 | Oct 3, 2024 | |
| ROIV Roivant Sciences | Reiterates: Overweight | n/a | $11.49 | - | 9 | Sep 19, 2024 | |
| LLY Eli Lilly | Reiterates: Overweight | $885 | $753.41 | +17.47% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.63 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.17 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.33 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.18 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.12 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $167.76 | +19.22% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.15 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.20 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.92 | - | 4 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.58 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.49 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.03 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $743.35 | +24.44% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.18 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $13.04 | +398.47% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.96 | - | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.05 | +376.19% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $0.98 | +2,451.02% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $17.96 | +178.40% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $10.18 | +391.16% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.34 | +273.13% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $2.82 | +219.15% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $21 | $0.30 | +6,846.74% | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $67,500 | $0.98 | +6,888,358.01% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $474.44 | -45.62% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $17.05 | -12.02% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.12 | +4,364.29% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.58 | +1,165.82% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $3.80 | +1,215.79% | 1 | Jul 21, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $5.23 | +760.42% | 1 | Jun 22, 2017 |
Spero Therapeutics
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.20
Upside: -
Novo Nordisk
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $103.15
Upside: +55.11%
Vaxcyte
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $85.96
Upside: -
Pfizer
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $24.80
Upside: +81.43%
Zai Lab
Oct 25, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.23
Upside: -
Johnson & Johnson
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $153.87
Upside: +39.73%
Zevra Therapeutics
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.97
Upside: -
Merck & Co.
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $97.44
Upside: +59.07%
Roivant Sciences
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.49
Upside: -
Eli Lilly
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $753.41
Upside: +17.47%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.63
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.17
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.33
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.18
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.12
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $167.76
Upside: +19.22%
Aug 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.15
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.20
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.92
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.58
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.49
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.03
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $743.35
Upside: +24.44%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.18
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $13.04
Upside: +398.47%
Nov 14, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.96
Upside: -
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.05
Upside: +376.19%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $0.98
Upside: +2,451.02%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $17.96
Upside: +178.40%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $10.18
Upside: +391.16%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.34
Upside: +273.13%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $2.82
Upside: +219.15%
May 10, 2023
Maintains: Neutral
Price Target: $33 → $21
Current: $0.30
Upside: +6,846.74%
Jul 7, 2021
Initiates: Overweight
Price Target: $67,500
Current: $0.98
Upside: +6,888,358.01%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $474.44
Upside: -45.62%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $17.05
Upside: -12.02%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.12
Upside: +4,364.29%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.58
Upside: +1,165.82%
Jul 21, 2017
Initiates: Overweight
Price Target: $50
Current: $3.80
Upside: +1,215.79%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $5.23
Upside: +760.42%